Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $110 | $269 | $773 | $1,730 |
| - Cash | $57 | $29 | $116 | $365 |
| + Debt | $3 | $4 | $0 | $0 |
| Enterprise Value | $57 | $244 | $657 | $1,364 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | -$1 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$118 | -$118 | -$90 | -$36 |
| % Margin | – | – | – | – |
| Net Income | -$113 | -$114 | -$89 | -$35 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.42 | -2.59 | -2.05 | -0.81 |
| % Growth | 6.6% | -26.3% | -153.1% | – |
| Operating Cash Flow | -$100 | -$89 | -$71 | -$30 |
| Capital Expenditures | $0 | -$3 | -$1 | -$0 |
| Free Cash Flow | -$100 | -$92 | -$72 | -$30 |